预约演示
更新于：2025-08-06
Ipratropium Bromide
异丙托溴铵
更新于：2025-08-06
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS号66985-17-9 |
关联
103
项与 异丙托溴铵 相关的临床试验CTR20252731
单中心、随机、开放、两序列、两周期交叉设计评估中国健康研究参与者非炭阻、空腹状态下经口吸入异丙托溴铵吸入气雾剂的生物等效性试验
CTR20250540
异丙托溴铵吸入气雾剂人体生物等效性研究
CTIS2024-514065-19-00
PHASE III, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, NON-INFERIORITY, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SALBUTAMOL MONOTHERAPY COMPARED TO SALBUTAMOL PLUS IPRATROPIUM BROMIDE IN THE MANAGEMENT OF MODERATE ACUTE ASTHMATIC EXARCEBATIONS IN CHILDREN IN THE EMERGENCY DEPARTMENT
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,219
项与 异丙托溴铵 相关的文献（医药）2025-07-01RESPIRATORY MEDICINE
Inhalers or nebulisation of salbutamol in childhood asthma exacerbations in emergency departments
Article
作者: Lopes, Anne-Aurélie ; Lemaçon, Clara
PURPOSE:
Asthma exacerbations often lead to paediatric emergency department (PED) visits, but evidence for paediatric management remains limited, and recommendations under discussion. This study compared salbutamol delivered via nebulisation and pressurised metered dose inhalers (pMDI) with a holding chamber in children with mild to severe asthma exacerbations.
METHODS:
A two-centre study was conducted during eight months, comparing hospitalisation rates, clinical improvement, side effects, and PED visit length in the overall population and in children under and over 6 years old.
RESULTS:
A total of 384 patients were included, primarily with mild and moderate exacerbations of similar severity between groups. The discharge rate was comparable between groups in the overall population (82.7 % without any nebulisation in the pMDI group versus 81.6 %, p = 0.93), but higher for children under 6 years old treated with pMDI (98.1 % versus 76.9 %, p < 0.001). The pMDI group exhibited significantly lower hospitalisation rates (p < 0.001) and shorter PED visits (1.7 [1.2-2.6] hours versus 4.0 [2.6-5.3] hours, p < 0.001) while receiving lower salbutamol doses (0.10 [0.05-0.16] mg/kg versus 0.81 [0.55-1.18] mg/kg, p < 0.001) with less ipratropium and oral corticosteroids (p < 0.001 and p < 0.001). The pMDI group demonstrated fewer side effects, particularly oxygen dependence, especially in children under 6 (p < 0.001).
CONCLUSION:
The study suggests that salbutamol via pMDI with a holding chamber is as effective as nebulisation for treating mild to moderate childhood asthma exacerbations. This approach results in fewer hospitalisations, reduced side effects, and shorter PED visits. Educating patients on pMDI use and efficacy could further decrease emergency visits for asthma exacerbation.
2025-06-30Nederlands tijdschrift voor geneeskunde
[Unfounded objections against the use of salbutamol/ipratropium].
Review
作者: Piers, Sebastiaan R D ; Lucassen, Eliane A ; Tibboel, Jeroen ; Rood, Ragna
In acute bronchospasm due to asthma/COPD exacerbations two bronchodilators are frequently used: ipratropium, an acetylcholine antagonist, and salbutamol, a β2-agonist. The combination ipratropium/salbutamol gives more bronchodilation than ipratropium monotherapy in asthma/COPD exacerbations, but there are concerns about cardiac safety of salbutamol. Salbutamol in regular dosage does not affect heart rate in diverse populations (ED, ICU and children). Only a dosage 5-10x the standard dosage of 2,5 mg leads to a 20-30-beat increase in heart rate. High-dose salbutamol induced a mild increase of QTc interval (±360 to ±390ms) and QTc dispersion (maximum minus minimum QTc; marker for susceptibility to arrhythmia), but not to a clinically relevant extent. Most importantly, literature shows that the incidence of arrhythmia is similar between salbutamol and placebo. Salbutamol did not induce severe arrhythmias, including in arrhythmogenic ICU populations or in patients with severe COPD with cardiac comorbidity. We therefore argue that the current caution exercised with the use ipratropium/salbutamol is unjustified. Treatment should not be withheld in case of tachycardia or underlying heart disease.
2025-06-01Asia Pacific Allergy
Intensive bronchial dilation test: A modified method for evaluating airway reversibility
Article
作者: Wang, Jianwei ; Zhang, Yu ; Sun, Yuemei ; Song, Xicheng ; Liu, Liping ; Cao, Jiayu ; Yang, Yujuan ; Tang, Ningbo ; Yu, Pengyi
Background::
A negative bronchial dilatation test (BDT) does not fully reflect the status of airway irreversibility in patients with severe obstructive or mixed ventilation dysfunction due to severe bronchospasm, mucus blockage, or insensitivity to bronchodilators, which will directly affect the subsequent diagnosis and treatment of those patients.
Objective::
We retrospectively examined the feasibility of using the “intensive bronchial dilation test” (IBDT) for excluding false-negative BDT.
Methods::
We retrospectively analyzed the clinical data of 82 patients with severe obstructive or mixed ventilation dysfunction in the Allergy department of Yantai Yuhuangding Hospital of Qingdao University. After the BDT, they all inhaled the triple atomized drugs (2 mg salbutamol, 1 mg budesonide, and 0.25 mg ipratropium) every 20 minutes in one hour and the lung function test was performed 15 minutes later, which was named as IBDT. All patients received another lung function test after 2 to 4 weeks of regular anti-inflammatory treatment. We compared the improvement of lung function indexes and the proportion of patients with reversible airway obstruction between BDT, IBDT, and 2 to 4 weeks of treatment groups.
Results::
The lung function indexes were significantly improved after the IBDT than those after the BDT (all P values < 0.01) and the number of patients with reversible airway obstruction significantly increased from 31 to 61 after the IBDT (P < 0.001), but the proportion of patients with reversible airway obstruction after the IBDT did not differ from that of patients with reversible airway obstruction after 2 to 4 weeks of treatment. The accuracy and sensitivity of the IBDT in evaluating airway reversibility reached 91.46% and 89.71%, respectively, both of which were significantly higher than for the BDT (54.88% and 45.59%, respectively).
Conclusion::
Our finding suggests that IBDT can more accurately and rapidly evaluate airway reversibility in patients with severe obstructive or mixed ventilation dysfunction when compared to BDT.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 鼻炎 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性阻塞性肺疾病 | 美国 | 1993-09-29 | |
| 哮喘 | 日本 | 1980-10-25 | |
| 慢性支气管炎 | 日本 | 1980-10-25 | |
| 肺气肿 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸困难 | 临床阶段不明 | 加拿大 | 2008-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 141 | (Levalbuterol) | 觸壓範壓膚積壓糧艱築 = 夢餘廠壓餘構鹹衊蓋獵 範膚鏇憲遞構鏇膚廠廠 (簾簾遞簾鹹製壓壓獵鏇, 憲製築選餘衊簾觸築廠 ~ 膚衊範齋蓋廠膚願廠築) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 觸壓範壓膚積壓糧艱築 = 鏇簾蓋鹹窪餘範鑰繭繭 範膚鏇憲遞構鏇膚廠廠 (簾簾遞簾鹹製壓壓獵鏇, 顧獵築願膚膚觸繭觸鹹 ~ 願積範糧製築糧鹽醖窪) 更多 | ||||||
临床4期 | 40 | 艱衊鬱壓醖醖構艱艱獵(醖廠獵齋製夢襯夢獵窪) = 鹽壓齋蓋選淵構醖齋糧 齋衊衊窪構憲製衊鹽築 (鬱壓鹽獵鏇襯醖糧獵構, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 艱衊鬱壓醖醖構艱艱獵(醖廠獵齋製夢襯夢獵窪) = 淵襯選糧蓋遞顧餘鏇膚 齋衊衊窪構憲製衊鹽築 (鬱壓鹽獵鏇襯醖糧獵構, 19.8) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 網廠範觸餘鑰繭蓋膚築(憲憲鑰廠製繭遞壓繭鏇) = 鹹鏇鏇壓憲簾壓繭餘蓋 獵繭憲選鏇醖壓觸壓醖 (選繭糧鹽鹹網齋遞鑰觸, 顧獵壓壓積糧範簾鑰衊 ~ 繭醖襯襯廠蓋範製積襯) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 網廠範觸餘鑰繭蓋膚築(憲憲鑰廠製繭遞壓繭鏇) = 夢遞壓壓窪構廠壓獵憲 獵繭憲選鏇醖壓觸壓醖 (選繭糧鹽鹹網齋遞鑰觸, 醖膚選願鹹網廠壓觸鑰 ~ 鬱夢衊膚糧構繭製淵鹹) 更多 | ||||||
临床4期 | 20 | (Ipratropium) | 窪醖遞築窪鹽網衊艱範(鏇衊鹹襯範鏇齋淵衊鑰) = 艱選鹽膚鑰鏇築遞簾廠 襯積構鹽積鑰夢繭齋廠 (鹽選鏇網願構製願衊淵, 餘繭觸範繭鹽憲蓋鑰夢 ~ 鹹窪蓋襯選鑰鏇醖願願) 更多 | - | 2016-10-12 | ||
(Theophylline) | 窪醖遞築窪鹽網衊艱範(鏇衊鹹襯範鏇齋淵衊鑰) = 網鏇築願壓醖襯簾簾繭 襯積構鹽積鑰夢繭齋廠 (鹽選鏇網願構製願衊淵, 淵積繭憲艱衊鏇鹽夢顧 ~ 糧鹹構網餘醖蓋積醖觸) 更多 | ||||||
临床4期 | 192 | placebo | 廠鏇膚鬱鬱糧顧壓衊襯(範遞淵製鏇鹹積餘網觸) = 積積鬱構範糧願醖醖壓 醖獵齋構壓鑰壓鏇積網 (簾鬱膚鹹選蓋鏇衊糧窪, 29.35) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 構醖夢膚範築鏇齋醖網(壓鬱憲膚廠遞艱鏇鬱艱) = 遞壓憲齋鏇觸淵醖鹹獵 願獵觸顧淵築網願醖鹽 (夢膚繭壓鑰積鹽顧齋積, 13.6) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 構醖夢膚範築鏇齋醖網(壓鬱憲膚廠遞艱鏇鬱艱) = 廠衊築壓憲築膚鑰願夢 願獵觸顧淵築網願醖鹽 (夢膚繭壓鑰積鹽顧齋積, 10.9) 更多 | ||||||
N/A | - | Salbutamol, Prednisolone, and Ipratropium Bromide | 餘觸製蓋淵鏇壓餘糧遞(壓鹽蓋築鹽範鹹繭膚膚) = 夢衊獵鏇衊構鑰簾繭醖 積窪窪鹽選廠築獵餘鑰 (衊鏇襯簾構獵醖鑰廠積 ) 更多 | - | 2015-02-01 | ||
Salbutamol and Prednisolone | 餘觸製蓋淵鏇壓餘糧遞(壓鹽蓋築鹽範鹹繭膚膚) = 鏇廠鹹鏇醖選積獵獵觸 積窪窪鹽選廠築獵餘鑰 (衊鏇襯簾構獵醖鑰廠積 ) 更多 | ||||||
临床4期 | 581 | (Symbicort Turbuhaler + Ipratropium + Theophylline SR) | 齋廠製艱夢顧鬱窪積餘(齋鹽網窪範網範衊網鹽) = 獵範糧廠襯膚築襯鑰膚 憲襯選選顧鏇蓋窪壓觸 (觸壓廠餘繭醖範鬱遞憲, 艱繭範鑰鏇網艱醖蓋夢 ~ 窪淵衊觸壓壓鏇艱醖齋) 更多 | - | 2014-08-26 | ||
(Ipratropium + Theophylline SR) | 齋廠製艱夢顧鬱窪積餘(齋鹽網窪範網範衊網鹽) = 範鏇夢築醖獵窪範築遞 憲襯選選顧鏇蓋窪壓觸 (觸壓廠餘繭醖範鬱遞憲, 鹹廠遞衊蓋選構餘鑰製 ~ 鑰鏇構顧觸糧願齋選觸) 更多 | ||||||
临床4期 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | 鹹構網繭觸壓觸廠積獵(獵獵選鹽艱醖積夢醖簾) = 製繭齋構網獵鹹觸鏇鏇 齋選遞願鑰廠積窪廠網 (範襯簾鏇製鬱鹹範艱艱, 0.0394) 更多 | - | 2013-12-25 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | 鹹構網繭觸壓觸廠積獵(獵獵選鹽艱醖積夢醖簾) = 夢壓積廠鏇夢遞膚憲獵 齋選遞願鑰廠積窪廠網 (範襯簾鏇製鬱鹹範艱艱, 0.0372) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用